title: Adverse Late and Long-Term Treatment Effects in Adult Allogeneic Hematopoietic Stem Cell Transplant Survivors.
abstract: Hematopoietic stem cell transplantation (HSCT) has become the standard of care for many malignant and nonmalignant hematologic diseases that don't respond to traditional therapy. There are two types: autologous transplantation (auto-HSCT), in which an individual's stem cells are collected, stored, and infused back into that person; and allogeneic transplantation (allo-HSCT), in which healthy donor stem cells are infused into a recipient whose bone marrow has been damaged or destroyed. There have been numerous advancements in this field, leading to marked increases in the number of transplants performed annually. This article--the first of several on cancer survivorship--focuses on the care of adult allo-HSCT survivors because of the greater complexity of their posttransplant course. The author summarizes potential adverse late and long-term treatment-related effects, with special focus on the evaluation and management of several cardiovascular disease risk factors that can occur either independently or concurrently as part of the metabolic syndrome. These risk factors are potentially modifiable with appropriate nursing interventions and lifestyle modifications.
authors.affiliation: Kara Mosesso is an NP at Memorial Sloan Kettering Cancer Center in New York City. Contact author: mosessok@mskcc.org. The author and planners have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Kara
authors.initials: K
authors.lastname: Mosesso
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D015897:Comorbidity; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D000069451:Long Term Adverse Effects; D024821:Metabolic Syndrome / Q000150:complications / Q000209:etiology; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D010198:Pancytopenia / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D011183:Postoperative Complications; D012074:Remission Induction; D012307:Risk Factors; D017741:Survivors / Q000706:statistics & numerical data; D014182:Transplantation, Autologous / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents